Analytical Method Development: SOP for Analytical Method Validation Planning – V 2.0
Standard Operating Procedure for Planning of Analytical Method Validation in AMD
| Department |
Analytical Method Development |
| SOP No. |
SOP/AMD/196/2025 |
| Supersedes |
SOP/AMD/196/2022 |
| Page No. |
Page 1 of 14 |
| Issue Date |
19/05/2025 |
| Effective Date |
20/05/2025 |
| Review Date |
19/05/2026 |
1. Purpose
To define the procedure for planning analytical method validation activities within the Analytical Method Development (AMD) department, ensuring compliance with ICH Q2(R2) guidelines and internal quality requirements.
2.
Scope
This SOP applies to the planning of validation of analytical methods developed for drug substances, drug products, excipients, and cleaning validations intended for use in Quality Control or regulatory submissions.
3. Responsibilities
- Analytical Scientist: Designs validation strategy and drafts validation protocol.
- QA Officer: Reviews and approves validation plan to ensure compliance with regulatory standards.
- Validation Analyst: Executes validation activities as per approved protocol.
- Head – AMD: Approves validation plan and authorizes execution.
4. Accountability
The Head of AMD is accountable for ensuring validation plans are scientifically justified, protocol-driven, and aligned with global regulatory expectations.
5. Procedure
5.1 Method Categorization
- Determine the type of analytical method:
- Identification
- Assay (Quantitative)
- Impurity Testing
- Limit Tests
- Dissolution
- Cleaning Validation
- Refer to ICH Q2(R2) to identify applicable validation parameters.
5.2 Validation Parameter Planning
- Based on method category, select validation characteristics:
- Specificity
- Linearity and Range
- Accuracy
- Precision (Repeatability and Intermediate Precision)
- LOD/LOQ
- Robustness
- System Suitability
- Ensure plan includes number of analysts, days, instruments, and concentrations to be tested.
5.3 Validation Protocol Development
- Prepare a protocol including:
- Objective and scope
- Method summary
- Validation parameters with acceptance criteria
- Statistical tools and evaluation plan
- List of equipment, reagents, and reference standards
- Use Annexure-1: Method Validation Planning Template to structure protocol sections.
- Submit to QA and Department Head for review and approval.
5.4 Execution and Schedule Planning
- Create a Gantt chart or schedule identifying timelines, personnel, and milestones.
- Ensure availability of:
- Calibrated equipment
- Qualified reference and working standards
- Trained analysts
- Document readiness in Annexure-2: Validation Preparation Checklist.
6. Abbreviations
- SOP: Standard Operating Procedure
- ICH: International Council for Harmonisation
- LOD: Limit of Detection
- LOQ: Limit of Quantification
- AMD: Analytical Method Development
7. Documents
- Method Validation Planning Template – Annexure-1
- Validation Preparation Checklist – Annexure-2
8. References
- ICH Q2(R2) – Validation of Analytical Procedures
- FDA Guidance – Analytical Procedures and Methods Validation
- Internal Quality Manual – Analytical Validation Planning
9. SOP Version
Version: 2.0
10. Approval Section
|
Prepared By |
Checked By |
Approved By |
| Signature |
|
|
|
| Date |
|
|
|
| Name |
|
|
|
| Designation |
|
|
|
| Department |
|
|
|
11. Annexures
Annexure-1: Method Validation Planning Template
| Section |
Details |
| Method Type |
Assay of API |
| Validation Parameters |
Specificity, Linearity, Accuracy, Precision, Robustness |
| Acceptance Criteria |
R² ≥ 0.998; Recovery 98–102%; RSD ≤ 2% |
| Statistical Tool |
ANOVA, Regression |
Annexure-2: Validation Preparation Checklist
| Item |
Status |
Remarks |
| Validated Equipment |
Available |
HPLC #0023 Calibrated |
| Qualified Analysts |
Yes |
Trained on SOP/AMD/196/2025 |
| Standards Availability |
Yes |
Reference standard batch RS-A005 |
Revision History:
| Revision Date |
Revision No. |
Details |
Reason |
Approved By |
| 04/05/2025 |
2.0 |
Revised to include validation planning checklist and template-based protocol structure |
Alignment with updated ICH Q2(R2) |
|